References
Pedersen RS, Brasch-Andersen C, Sim SC et al (2010) Linkage disequilibrium between the CYP2C19*17 allele and wildtype CYP2C8 and CYP2C9 alleles: identification of CYP2C haplotypes in healthy Nordic populations. Eur J Clin Pharmacol. doi: 10.1007/s00228-010-0864-8 2010
Sim SC, Risinger C, Dahl ML et al (2006) A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 79:103–113
Suarez-Kurtz G, Genro JP, de Moraes MO et al (2010) Global pharmacogenomics: impact of population diversity on the distribution of polymorphisms in the CYP2C cluster among Brazilians Pharmacogenomics J (in press)
Dai D, Zeldin DC, Blaisdell JA et al (2001) Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 11:597–607
Cavaco I, Piedade R, Gil JP, Ribeiro V (2006) CYP2C8 polymorphism among the Portuguese. Clin Chem Lab Med 44:168–170
Parikh S, Ouedraogo JB, Goldstein JA, Rosenthal PJ, Kroetz DL (2007) Amodiaquine metabolism is impaired by common polymorphisms in CYP2C8: implications for malaria treatment in Africa. Clin Pharmacol Ther 82:197–203
Parra FC, Amado RC, Lambertucci JR, Rocha J, Antunes CM, Pena SDJ (2003) Color and genomic ancestry in Brazilians. Proc Natl Acad Sci USA 100:177–182
Suarez-Kurtz G, Vargens DD, Struchiner CJ, Bastos-Rodrigues L, Pena SDJ (2007) Self-reported skin color, genomic ancestry and the distribution of GST polymorphisms. Pharmacogenet Genomics 17:765–771
Kudzi W, Dodoo AN, Mills J (2009) Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population. BMC Med Genet 10:124
Drögemöller BI, Wright GE, Niehaus DJ et al (2010) Characterization of the genetic profile of CYP2C19 in two South African populations. Pharmacogenomics 11:1095–1103
Ahmadi KR, Weale ME, Xue ZY et al (2005) A single-nucleotide polymorphism tagging set for human drug metabolism and transport. Nat Genet 37:84–89
Speed WC, Kang SP, Tuck DP, Harris LN, Kidd KK (2009) Global variation in CYP2C8–CYP2C9 functional haplotypes. Pharmacogenomics 9:283–290
Totah RA, Rettie AE (2005) Cytochrome P450 C28: substrates, inhibitors, pharmacogentics and clinical relevance. Clin Pharmacol Ther 77:341–352
Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C (2007) Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 116:496–526
Li-Wan-Po A, Girard T, Farndon P, Cooley C, Lithgow J (2010) Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17. Br J Clin Pharmacol 69:222–230
Gaun TR, Rodriguez S, Day INM (2007) Cubic exact solutions for the estimation of pairwise haplotype frequencies: implications for linkage disequilibrium analyses and a web tool ‘CubeX’. BMC Bioinform 8:428
Acknowledgements
GS-K is supported by grants from the Brazilian agencies Financiadora de Estudos e Projetos (FINEP), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) and Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Suarez-Kurtz, G. Linkage disequilibrium between the CYP2C19*17 and CYP2C8*2 alleles in populations of African descent. Eur J Clin Pharmacol 67, 211–212 (2011). https://doi.org/10.1007/s00228-010-0910-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-010-0910-6